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Abstract: The anti-NK1.1 antibody produced by PK136 hybridoma cell line administered subcutaneously to SCID mice
effectively decreased the level of peripheral blood NK cells and weight of the spleen for 3-4 days. The antibody treatment did
not harm the general state of the animal, and may be practically applied in xenograft experiments. (www.cm-uj.krakow.pl/FHC)
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Introduction
The organism of SCID mice (Severe Combined Immu-
noDeficiency) has normal internal microenvironment
for hemopoiesis, and develop mature monocytes, poly-
morphonuclear leukocytes, megakaryocytes, erythro-
cytes and NK cells. The mice, however, lack both
humoral and cell-mediated immunity due to the absence
of mature B and T lymphocytes [5]. As the specific
immunity of SCID mice is invalid, the organism is used
as a convenient model animal for implantation of human
normal or pathological cells or organs [14]. Even the
mouse with functional human hemopoietic system may
be constructed within SCID mouse [4]. The problem is,
however, the presence of mouse NK cells attacking the
implanted cells. 
A convenient method for prolongation of the trans-
plant survival is treatment of the animal with chemother-
apeutics (cyclophosphamide, busulfan) [4] or irradiation
[8] before xenotransplant implantation. However, the
treatment with cytostatics or irradiation, damages not
only NK-cells, but also cells of several other tissues and
organs, what may influence the result of the experiment.
The treatment of mice with specific anti-mouse NK-
cells antibody would probably prevent the unwanted
host tissue damage. We could not find bibliography
concerned with the number of NK cells in the SCID mice
after treatment with the anti-NK1.1 antibody. The
presented results describe the changes in the number of
NK cells in the peripheral blood and in the spleen of
anti-NK1.1 antibody-treated SCID animals. 
Materials and methods
Mice. The animals were pathogen-free, our own breeding, 10-12
weeks old severe combined immunodeficient (SCID) mice [5],
C.B-17/IcrHan-Hsd-scid; first families were from Harlan Shaws
Farm, UK. Animals were housed in sterilized microisolator cages
and received autoclaved food and drinking water. The mice were
systematically controlled for the absence of B and T lymphocytes
with the mouse anti-CD19 PE (clone 1D3) and mouse anti-CD3
FITC (clone 17A2), both from Pharmingen. The Local Ethical Com-
mittee approved the experiment on animals.
Anti-NK cell antibody. The mice hybridoma cell line (PK136),
secreting mouse IgG2a monoclonal antibody reacting with mice NK
cells [12] was obtained from the American Type Culture Collection
(ATCC). The antibody is specific for NK cells and is cytotoxic in the
presence of mouse complement. The SCID C.B-17 mice have high
level of complement. The monoclonal antibody reactivity with
mouse NK cells was tested cytometrically after IgG2a labeling with
the Zenon Alexa Fluor 488 Mouse IgG2a Labeling Kit (lot 75C3-1)
from Molecular Probes. Labeling does not require monoclonal anti-
body pre-purification. The reactivity of PK136 monoclonal antibody
is equivalent to anti-NK1.1 antibody [12]. The PK136 cells were
maintained in complete RPMI 1640 culture medium supplemented
with 10% fetal calf serum (FCS) and antibiotics. The one-day culture
medium supernatant collected from several parallel cultures was
combined, divided into 1ml portions, and stored frozen at -80oC. The
thawed culture medium was used as the source of antibody for
experiments. The antibody concentration in the culture medium was
estimated by adsorption on protein A-Sepharose column (Pharmacia,
lot No 17-0780-01). The eluted IgG fraction was estimated spectro-
fotometricaly by A280 absorption assuming absorbance coefficient of
IgG=138 [17]. The IgG concentration in the culture medium given
to the mouse was 8 µg/ml.
SCID mouse treatment with anti-NK cells antibody. The PK136
culture medium containing anti-NK1.1 antibody was administered
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subcutaneously once, twice or three times to the animal with 2-day
intervals, in the dose of 0.5 ml (4 µg IgG) per animal. The optimal
amount of mAb for in vivo NK cell depletion was determined in
preliminary experiment by flow cytometry (data not shown), using
anti-mouse NK cells antibody (Pan NK Cell PE clone DX5, Pharm-
ingen), in the peripheral blood of treated animals. One, 2, 3 or 4 days
after the last injection, the mice were sacrificed and the peripheral
blood and spleen were collected. The peripheral blood WBC (white
blood cells/µl), weight of the spleen and number of spleno-
cytes/organ were determined.
Flow cytometry and statistics. The percentage and number of NK
cells/µl were analyzed with anti-mouse NK cells antibody (Pan NK
Cell PE clone DX5, Pharmingen) and flow cytometry (Becton-Dick-
inson FACSCalibur) using CellQuest application. The immunocyto-
chemical procedure was as described previously [9]. The median and
percentile values were calculated for experiments repeated at least 3
times. The statistically significant difference of results was assumed
for p<0.05 in Mann-Whitney U-test.
Results
In peripheral blood of SCID mouse, WBC 825/µl was
observed and NK cells amounted to 303/µl in lympho-
cyte gate (Table 1). The percent of peripheral blood NK
cells was 35% in SCID mice. The absolute values of cell
populations (NK cells/µl) are more informative than the
relative values.
An example of mouse peripheral blood analysis
using flow cytometry, 48 h after a double treatment with
anti-NK1.1 antibody is presented in Figure 1. The num-
ber of lymphocytes per 10 000 leukocytes decreased
from 2657 in the control animal (Fig. 1A) to 1045 in the
anti-NK1.1 antibody treated mouse (Fig. 1B). Anti-NK-
PE positive cells were 3-times lower after treatment (817
cells) than in untreated animal (2357 cells). Two anti-
NK1.1 positive cell subpopulations could be observed,
one with higher expression of the antibody-recognized
domain.
The changes in peripheral blood NK cells depended
on the dose of antibody (Table 1). Significantly lower
number or NK cells/µl was observed after double or
triple anti-NK1.1 antibody treatment. The weight of
spleen and the number of splenocytes also decreased in
3-times treated animals. However, there was no deterior-
ation of the general state of the treated animals such as
lower weight, observed after cyclophosphamide treat-
ment (not presented).
The number of peripheral blood NK cells lowered by
anti-NK1.1 antibody treatment rose with time after the
last antibody dose (Table 1, 1 × antibody treatment).
However 3-4 days after single administration of the
antibody, the number of peripheral blood NK cells/l in
animal still remained lower by 1/3 as compared with the
control, untreated animals. 
Discussion
The scid mutation was first described in 1983 in CB-17
strain mice [6]. The CB-17 mice are of BALB/c strain
with the disrupted gene termed "DNA dependent protein
kinase, catalytic subunit" (DNA-PKCS, synonym Prkdc)
[11,13]. The Prkdcscid gene encodes a nonsense mutation
which causes the insertion of a termination codon [2].
The lack of an adaptive immune system in SCID mice
results from their inability to express rearranged antigen
receptors. This is due to a failure to activate a DNA
recombinase that requires a functional Prkdc gene. As
NK cells do not need that enzyme for their function, their
activity is undisrupted in CB-17 SCID mice. 
CB-17 SCID mice show increased levels of NK cell
activity [1]. To eliminate NK cells, SCID mice were
treated with anti-asialo GM1 antibody to deplete host
NK cells prior to successful implantation of human
postnatal thymus [3]. Anti-NK antibody (anti-asialo
Table 1. Peripheral blood WBC, number of peripheral blood NK cells, weight of the spleen and number of splenocytes/organ in SCID mice
treated with anti-NK1.1 antibody. 
Untreated
Ab treatment 1× Ab treatment 2× Ab treatment 3×
day 2 day 3 day 4 day 1 day 3 day 3
WBC 
cells/µl
825
(550-1125
800
(500-988)
1000
(888-1188)
650
(613-988)
1000
(888-1053)
900
(600-900)
400 #
(400-588)
NK
% cells
35
(28-42)
15*
(15-19)
14*
(13-19)
21
(20-23)
10*
(9-11)
13*
(12-15)
13*
(12-16)
NK
cells/µl
303
(266-377)
145*
(112-175)
208*
(175-223)
195
(169-252)
109*
(97-117)
142*#
(114-147)
86*#
(79-139)
spleen weight
mg
44.8
(44-51)
43.1
(42-46)
41.1
(37-45)
55.4
(41-50)
37.1*
(35-39)
35.7
(29-44)
27.8*#
(27-28)
splenocytes/
organ × 106
29.3
(23-35)
26.7
(23-36)
21.9
(21-28)
23.6
(19-32)
15.1*
(15-17)
25.4
(15-25)
15.1*
(11-16)
The animals were treated once, 2-times or 3-times and analyzed on the indicated day after the last treatment. Median and percentile values
(P25-P75) from n = 3 assays or for untreated control, otherwise n = 4.
p<0.05 as compared with control* or compared with 1× Ab-treated animals#, analyzed on day 3.
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GM1) in mice enhanced engraftment and chimerism of
allogenic fetal liver stem cells as well [7]. In our experi-
ment, however, another anti-NK antibody (anti-NK1.1)
was found to decrease the number of NK cells for 3-4
days without any harm to the animal. Probably the
continuous treatment with the antibody would prolong
the xenograft, e.g. human B-chronic lymphocytic cells
(B-CLL) survival in SCID mice [10]. Similar experi-
ments on treatment with antisense oligodeoxynucleo-
tides of SCID mice with implanted human K562,
bcr/abl-positive cell line [15], could be extended in
animals treated with anti-NK1.1 antibody. 
Apart from the practical application in xenografting
experiments in SCID mice, the short period (3-4 days)
of NK cell decrease gives a posibility to observe the
renewal of these cells. In the model with anti-NK1.1
antibody animal treatment, an information on the role of
NK cells in vivo may be obtained, e.g. in experiments
testing the role of NK1.1 cells in protection against MHC
Class I+ HPV16-associated tumors [16]. 
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